Vanguard Group Inc Arvinas, Inc. Call Options Transaction History
Vanguard Group Inc
- $5.12 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ARVN
# of Institutions
220Shares Held
68.8MCall Options Held
166KPut Options Held
31.3K-
Eco R1 Capital, LLC San Francisco, CA6.73MShares$178 Million6.33% of portfolio
-
Black Rock Inc. New York, NY6.26MShares$165 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.99MShares$105 Million0.01% of portfolio
-
Avidity Partners Management LP Dallas, TX2.99MShares$79 Million3.91% of portfolio
-
Rtw Investments, LP New York, NY2.97MShares$78.4 Million1.32% of portfolio
About ARVINAS, INC.
- Ticker ARVN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,205,300
- Market Cap $1.41B
- Description
- Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...